Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.

Archives of dermatology - 1 Nov 2006

Deng April, Gocke Christopher D, Hess John, Heyman Meyer, Paltiel Michael, Gaspari Anthony

Abstract excerpt

BACKGROUND: Livedoid vasculopathy (LV) is an occlusive thrombotic disease that affects primarily the small blood vessels of the lower extremities and often is associated with recurrent painful ulcerations. The pathogenesis of LV is unclear, but the disease is largely attributed to a hypercoagulable state. Factor V Leiden mutation, heterozygous protein C deficiency, homozygous hyperhomocysteinemia, and other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Heparin

Share to Plasminogen Activator Inhibitor 1

Share to Promoter Regions, Genetic

Share to Tissue Plasminogen Activator

Source

Identifiers

PMID: 17116837
DOI: 10.1001/archderm.142.11.1466

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.PMID 17116837Read ↗

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.Semantic proximity Read ↗

Livedoid vasculopathy and its association with genetic variants: A systematic review.Semantic proximity Read ↗

Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation.Semantic proximity Read ↗

A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin.Semantic proximity Read ↗

Failure to lyse venous thrombi because of elevated plasminogen activator Inhibitor 1 (PAI-1) and 4G polymorphism of its promotor genome (The PAI-1/4G Syndrome).Semantic proximity Read ↗

Plasminogen Activator Inhibitor-1 Levels and PolymorphismsSemantic proximity Read ↗

Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis.Semantic proximity Read ↗

Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity.Semantic proximity Read ↗

Livedoid vasculopathy: thrombotic or inflammatory disease?Semantic proximity Read ↗

Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 GeneSemantic proximity Read ↗

A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.Semantic proximity Read ↗

Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.